What Should Follow-Up Appointments Cover for Cannabis-Based Medicines?

Cannabis-based medicines are increasingly prescribed in the NHS for a handful of specific conditions, yet follow-up care remains a critical piece in ensuring safety, measuring benefits, and making informed decisions about continued use. This article unpacks what effective follow-up appointments should cover when a healthcare professional prescribes cannabis-based products.

Understanding the Symptom Being Treated: Autism vs Co-Occurring Conditions

One of the most important starting points when discussing cannabis-based medicines is clarifying what symptom or condition is being treated. It's essential to distinguish between autism itself—a neurodevelopmental condition characterized by differences in social communication and restricted, repetitive behaviors—and co-occurring conditions that individuals with autism may experience.

Key reality: No reputable professional body, including NICE (National Institute for Health and Care Excellence), recommends cannabis-based medicines to treat autism itself. Instead, some clinicians may cautiously trial cannabis-based products for challenging symptoms related to co-occurring conditions, such as severe epilepsy or treatment-resistant spasticity.

Stop point: If you hear "we treat autism with cannabis," that is a red flag demanding further clarification. Always ask: which specific symptom or condition are we targeting here? Without that clarity, follow-up lacks focus.

NICE Guidance on Cannabis-Based Medicines: What It Covers and What It Does Not

The NICE guidance library provides UK NHS clinicians with authoritative recommendations. When it comes to cannabis-related therapies, NICE has evaluated the evidence carefully and issued technology appraisals and guidelines reflecting their conclusions.

According to NICE:

Licensed cannabis-based medicines are currently approved only for specific epilepsy syndromes—Dravet syndrome, Lennox-Gastaut syndrome—and for certain spasticity symptoms linked to multiple sclerosis.
Evidence for efficacy outside these indications is limited and does not support routine prescribing.
NICE does not recommend cannabis-based products for behavioral or psychological symptoms of autism.
Caution is urged because of variable product quality and uncertainty regarding long-term effects.

Therefore, follow-up appointments should reflect these evidence-based boundaries. They should not become opportunities for off-label or blanket use https://londoninsider.co.uk/medical-cannabis-and-autism-what-london-families-should-know/ without documented clinical reasoning, informed consent, and a robust plan for monitoring.

Narrow Epilepsy Indications: Dravet and Lennox-Gastaut Syndromes

One of the few well-supported uses for cannabis-based medicines in the NHS is in treating certain severe, treatment-resistant childhood epilepsies: Dravet syndrome and Lennox-Gastaut syndrome. In these cases, cannabidiol (CBD) formulations such as Epidyolex have been licensed and endorsed by NICE.

Follow-up appointments here serve several critical functions:

Assessing seizure frequency and severity: Detailed seizure diaries or electronic tracking tools should be reviewed to gauge therapeutic effectiveness.
Monitoring side effects: Common side effects like drowsiness, gastrointestinal symptoms, or elevated liver enzymes require regular evaluation and sometimes blood testing.
Measuring quality of life changes: Both patient and caregiver reports about sleep, mood, or daily functioning can help build the broader picture.
Medication interactions: CBD affects liver enzymes and may alter levels of anti-epileptic drugs, necessitating careful pharmaceutical oversight.

Robust follow-up ensures the delicate balance between reducing seizures and maintaining safety, supporting the decision to continue or stop in line with the best current evidence.

Reviewing Side Effects: A Non-Negotiable Component

Side effects review must be a cornerstone of follow-up appointments when cannabis-based medicines are involved. Because these drugs can impact multiple systems, clinicians should routinely ask about and document:

Drowsiness, sedation, or changes in alertness levels
Gastrointestinal symptoms including nausea or diarrhea
Mood and behavioral changes such as irritability or anxiety
Liver function abnormalities (if lab results are available)
Any new or worsening symptoms potentially linked to the medicine

The General Medical Council (GMC) supports thorough side effect discussions as part of its principles for responsible prescribing. Patients and families should feel empowered to report any changes promptly.

Outcome Measurement: Beyond “Seems Calmer”

Anecdotal reports like "seems calmer" or "better behaved"—without objective measurement—create problems. Unstructured, subjective impressions risk placebo effects and confirmation bias, making it impossible to truly discern benefit.

Effective follow-up appointments include:

Use of standardized assessment tools: For epilepsy — seizure counts/logs; for spasticity — muscle tone scales; for co-occurring behavioral symptoms — validated scales relevant to the condition.
Baseline and follow-up comparisons: Documenting initial severity and tracking changes at prespecified intervals.
Clear goals and milestones: Agreeing upfront what treatment success looks like and reassessing accordingly.
Regular review of medication adherence: Understanding whether dosing is consistent helps interpret outcomes objectively.

This rigour reduces reliance on hand-wavy outcomes and supports meaningful clinical decisions.

Evidence Limits and Placebo Effects: What Clinicians and Families Should Know

It's important to acknowledge the limits of current evidence. For many indications outside of the narrow NICE-approved licenses, studies are small, open-label, or anecdotal, with high risk of bias. Placebo effects—where patients improve simply due to expectation—are well documented in neurological and psychiatric settings.

A transparent follow-up appointment recognizes these limitations through:

Discussing known evidence gaps openly with families
Emphasizing that continued use is conditional on measurable benefit outweighing risks
Implementing trial periods with planned stopping points if no improvement is detected
Encouraging questions and shared decision-making informed by best available data

Checklist: What to Cover During Follow-Up for Cannabis-Based Medicines

Follow-Up Component Purpose Action Items Confirm symptom/condition treated Ensure focus and appropriateness(Autism core vs co-occurring condition) Review initial indication; clarify treatment goals Side effects review Safety monitoring Ask about sedation, GI symptoms, mood changes; check labs if needed Outcome measurement Evidence of effectiveness vs placebo Use standardized scales; review logs/diaries Medication adherence and interactions Ensure consistent dosing; avoid harmful interactions Discuss regimen; check other meds Shared decision discussion Decide whether to continue or stop Review data; confirm understanding; plan next steps Document and report Maintain clear records aligned with GMC guidance Update notes; flag issues; consider reporting adverse events

Conclusion: Responsible Follow-Up Is Key

In summary, follow-up appointments for cannabis-based medicines must be detailed, evidence-informed, and patient-centered. They should clearly define the treated symptom, rigorously document side effects, use validated outcome measures, and involve transparent decision-making grounded in the latest NICE guidance and GMC standards.

Doing so respects the complex realities of neurodevelopmental and neurological disorders, acknowledges limits in current evidence, and ultimately protects patients and families from unproven or unsafe use. As the research evolves, so too should our approach—but the fundamentals of good clinical follow-up remain steadfast.

References and further reading:

NICE Technology Appraisal TA588: Epidyolex for treating seizures associated with Dravet or Lennox-Gastaut syndrome
GMC Prescribing Guidance
NICE Guidance Library